Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and
A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide)
Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progressi
This study elucidates drug resistance patterns and genotype-phenotype correlations in multidrug-resistant Mycobacterium tuberculosis strains from Hainan Island, China, revealing implications for tailored MIC-based therapies.
A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.